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have substantial latitude in de-
fining minimum benefits for 
Medicaid and private insurance 
plans, including the breadth of 
prescription-drug coverage, which 
could substantially affect the 
quality of HIV care.
Although most HIV-infected 
patients should be better off, 
some will continue to fall through 
insurance-coverage cracks. Many 
immigrants are excluded from 
coverage provisions; paperwork 
and eligibility requirements may 
make it difficult for low-income 
patients to navigate the enroll-
ment and reenrollment processes; 
and out-of-pocket costs for health 
insurance premiums and copay-
ments may affect uptake and 
utilization of private insurance. 
Consequently, there will contin-
ue to be an important role for 
safety-net funding sources. How-
ever, the future of the Ryan 
White program and other dis-
cretionary safety-net programs 
that support the workforce of 
HIV care providers is uncertain; 
the current authorization for the 
Ryan White program expires in 
2013. Major reductions in safety-
net funding would make it dif-
ficult to support HIV-infected 
patients who cannot successful-
ly navigate the new environment 
or afford subsidized insurance 
with sufficiently generous bene-
fits to cover their care. Finally, 
the shift of funding from safety-
net hospitals to community health 
centers may reduce capacity at 
HIV clinics affiliated with hospi-
tals serving low-income patients.
The rationale for a grade A rec-
ommendation from the USPSTF 
is that there is “high certainty 
that the net benefit is substan-
tial.”2 In the case of HIV screen-
ing, that benefit can be achieved 
only if people identified as HIV-
infected are effectively linked to 
and retained in HIV care and are 
supported in adhering to an effec-
tive antiretroviral regimen. The 
proposed USPSTF recommenda-
tions may remove financial bar-
riers to routine HIV screening, 
but that is only the first step in 
ensuring that all HIV-infected 
Americans have access to the 
full continuum of care.
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The history of the HIV–AIDS epidemic was profoundly al-
tered by the introduction of anti-
retroviral therapy (ART). More 
than 8 million people in low- 
income and middle-income coun-
tries have received lifesaving ART 
over the past decade, yet in 2011 
an estimated 34 million people 
were living with HIV infection, 
6.8 million were eligible for treat-
ment but lacked access to ART, 
2.5 million became newly infect-
ed, and 1.7 million died of HIV-
related disease.1
Long-standing debate regard-
ing the appropriate timing of ART 
initiation in the course of HIV 
infection was recently accentu-
ated by the recognition of the 
prevention benefit that ART pro-
vides by reducing viral load and 
infectiousness. Mathematical mod-
els, ecologic analyses, and results 
from the HIV Prevention Trials 
Network (HPTN) study HPTN 
052, a randomized, controlled 
trial that showed reduced HIV 
transmission from early, as com-
pared with deferred, ART in the 
infected member of an HIV-dis-
cordant couple,2 all stimulated 
discussion of a “test and treat” 
approach, whereby all HIV-infect-
ed persons would initiate ART im-
mediately after their HIV diagno-
sis, with anticipated reductions 
in transmission. A fundamental 
question remaining is what is best 
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for the health of the HIV-infected 
people who would take therapy 
for prevention, especially those in 
sub-Saharan Africa.
In the mid 1990s, we gained 
a clearer understanding of HIV 
replication and pathogenesis, viral-
load testing, and protease inhibi-
tors, and studies showed the ef-
ficacy of triple ART in patients 
with HIV disease. “Hit early, hit 
hard” was a prevailing theme re-
flected in U.S. guidelines. Early 
therapeutic aggressiveness and 
optimism, however, became tem-
pered by concerns about side ef-
fects and drug resistance, and 
the pendulum swung back toward 
guidelines more strongly support-
ed by evidence from clinical trials 
and rigorous evaluations (see fig-
ure). For the first 6 years of this 
century, the Department of Health 
and Human Services (DHHS) rec-
ommended — on the basis of 
clinical-trial evidence — that 
ART be initiated when the CD4+ 
count dropped to less than 200 
cells per cubic millimeter. As 
more durable and patient-friend-
ly therapies were developed, this 
threshold was progressively raised 
and, largely on the basis of ex-
pert opinion, the 2012 DHHS 
guidelines essentially advocate 
treatment for anyone living with 
HIV infection.3
There is strong evidence and 
agreement that patients with CD4+ 
counts of less than 200 cells per 
cubic millimeter are at greatly 
increased risk for AIDS-related 
events and death and therefore 
urgently require ART. Since a ran-
domized, controlled trial in Haiti 
showed reduced morbidity and 
mortality among persons in whom 
ART was initiated at a CD4+ 
count of 350 cells per cubic milli-
meter, as compared with those 
in whom therapy was deferred,4 
that CD4+ level is now the min-
imum ART-initiation threshold 
globally, including under World 
Health Organization (WHO) 
guidelines.5
Some experts argue for even 
earlier initiation: full immuno-
logic recovery lags if ART is un-
duly delayed, and uncontrolled 
HIV replication, irrespective of 
CD4+ count, results in immune 
activation and inflammation. 
These effects are probably caus-
ally related to many of the non-
























































Evolution of CD4+ Count Criteria for Starting Antiretroviral Therapy in Asymptomatic Persons with Human Immunodeficiency Virus 
Infection, According to Different Guidelines.
Criteria for the United States are from the Department of Health and Human Services Guidelines for Use of Antiretroviral Therapy 
in Adults and Adolescents, those for Europe are from the European AIDS Clinical Society guidelines, and those for the World Health 
Organization (WHO) are from the WHO Antiretroviral Therapy Guidelines for Adults and Adolescents. Adapted from Marco Vitoria, 
M.D., of the World Health Organization.
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fection, such as cardiovascular 
disease and non-AIDS cancers, 
that are now the primary causes 
of death among HIV-infected peo-
ple in high-income countries. 
Whether earlier ART would pre-
vent such complications remains 
unknown. Results from observa-
tional studies examining the ef-
fect of early initiation on preven-
tion of AIDS-related events and 
death are conflicting, and those 
investigations have focused solely 
on patients in industrialized coun-
tries. In addition to its primary 
aim of examining the prevention 
of HIV transmission in discordant 
couples, HPTN 052 compared 
clinical outcomes with early versus 
deferred therapy. However, it was 
not powered to examine mortality, 
the deferred-therapy group began 
receiving ART at CD4+ counts 
below the currently recommend-
ed threshold, and the clinical 
benefit that was observed was 
largely restricted to prevention of 
extrapulmonary tuberculosis.2
Uncertainty regarding the best 
approach to care for persons with 
higher CD4+ counts (>350 cells 
per cubic millimeter) is evident 
in the various guidelines that 
have been promulgated over the 
years (see figure). We need de-
finitive data on which to base 
guidelines. To address the ques-
tion of risks versus benefits of 
early ART initiation, the Nation-
al Institutes of Health is support-
ing the Strategic Timing of Anti-
retroviral Treatment (START) 
study (ClinicalTrials.gov number, 
NCT00867048), in which HIV-
infected persons with CD4+ 
counts of more than 500 cells 
per cubic millimeter are being 
randomly assigned to immediate 
ART or deferral until the count 
falls to 350 cells per cubic milli-
meter. The trial was designed to 
examine the effect of ART on 
noninfectious, non-AIDS com-
plications of HIV infection that 
predominate in higher-income set-
tings. Since relatively few patients 
from Africa are participating, it is 
unlikely that all uncertainties re-
lated to African settings will be 
addressed.
At least two thirds of people 
living with HIV infection are in 
sub-Saharan Africa, where frag-
ile health systems, health work-
force shortages, weak laboratory 
infrastructure, and fiscal con-
straints are ubiquitous. Debates 
about how best to use ART for 
both prevention and individual 
health are most relevant to the 
generalized HIV epidemics in this 
poorest geographic region.
The spectrum of HIV disease 
varies internationally because of 
varying exposures and varying 
diagnostic and therapeutic ca-
pacity. Bacterial infections and 
tuberculosis dominate as causes 
of disease and death among HIV-
infected people in Africa. The 
highest rate of adverse outcomes 
occurs among people with the 
lowest CD4+ counts, but the inci-
dences of tuberculosis and bacte-
rial infection are also increased 
at counts of 350 to 500 cells per 
cubic millimeter, and perhaps 
even at higher counts. Tuberculo-
sis rates have increased by a fac-
tor of 5 to 10 in sub-Saharan Af-
rica since the HIV–AIDS epidemic 
began. Mathematical modeling 
and a meta-analysis of treatment 
experience in resource-poor set-
tings suggest that early ART 
could reduce the incidence of tu-
berculosis among patients with a 
wide range of CD4 counts, but 
conclusive data are lacking.
Early initiation of ART in Afri-
ca might also prevent HIV trans-
mission. Mathematical models 
predict a large-scale effect from 
immediate ART use by all infect-
ed persons. Large-scale, commu-
nity-based trials of combination 
preventive interventions, including 
the test-and-treat approach, are 
being planned, but unanswered 
questions about individual health 
benefits versus risks raise ethical 
and pragmatic issues. Should uni-
versal therapy be promoted for 
the common good of prevention, 
despite an uncertain health ben-
efit for the person being treated? 
If immediate ART were shown to 
benefit individual health, the 
public health prioritization of the 
test-and-treat approach would be 
simplified, since it would be ap-
propriate to offer diagnosis and 
immediate ART to everyone.
Demonstration of the dual 
benefit of ART has generated 
optimism about containing the 
HIV–AIDS pandemic. The diver-
sity of clinical guidelines and 
practice, however, reflects a lack 
when to start art in africa
At least two thirds of people living with HIV 
infection are in sub-Saharan Africa.  
Debates about how best to use ART for both 
prevention and individual health are most 
relevant to the generalized HIV epidemics  
in this poorest geographic region.
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of definitive data indicating what 
is best for the persons who 
would be taking the drugs. The 
WHO characterizes the evidence 
available for informing the devel-
opment of guidelines on ART ini-
tiation as weak, and changes in 
U.S. guidelines have been based 
largely on expert opinion.
We believe that a randomized, 
controlled trial should be under-
taken immediately to determine 
when to initiate ART in Africa 
for maximal individual health 
benefit. It is feasible to conduct a 
large, simple trial to assess the 
risks and benefits of immediate 
ART versus deferral until a CD4+ 
count of 350 cells per cubic milli-
meter is reached. Key end points 
could be easy-to-ascertain events, 
such as tuberculosis incidence, 
hospitalization, and death. Equi-
poise would be present because 
of the conflicting evidence from 
observational studies, the absence 
of data from sub-Saharan Africa, 
limited data from randomized 
trials, divergent international prac-
tice, and inconsistent guidelines.
Uncertainty about ART is detri-
mental to the millions of people 
living with HIV infection. Early 
ART and deferred ART, each rec-
ommended and practiced de-
pending on the setting, cannot 
both be the most favorable choice 
for individual health. To make 
informed decisions, HIV-infected 
people require a full understand-
ing of the implications of taking 
ART early or late — or some may 
be reluctant to take early treat-
ment for prevention. With mil-
lions of people who require ART 
still not receiving it, billions of 
dollars invested in HIV–AIDS 
programs, and widespread dis-
cussion about extending ART use, 
too much is at stake to allow un-
certainty about when to initiate 
ART to persist.
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The Step 2 Clinical Skills Exam — A Poor Value Proposition
Elmer Philip Lehman IV, M.D., M.P.P., and Jason Ross Guercio, M.D., M.B.A.
Efforts to minimize the regu-latory and administrative bur-
den in U.S. health care have never 
been greater. Stakeholders, in-
cluding physicians, increasingly 
focus on eliminating waste and 
reducing costs in these areas to 
maximize the value and efficiency 
of care. One regulatory domain 
that deserves greater scrutiny in 
this context is medical licensure.
For example, the National 
Board of Medical Examiners 
(NBME) and the Federation of 
State Medical Boards (FSMB) 
mandate the purchase of four li-
censing products by medical stu-
dents and resident physicians 
over the course of their training. 
This three-step series of exami-
nations is known as the United 
States Medical Licensing Exami-
nation (USMLE) and is jointly 
administered by the NBME and 
FSMB. The second exam, Step 2, 
is itself a two-part test adminis-
tered in two sittings. One com-
ponent, Step 2 Clinical Knowl-
edge, is a multiple-choice exam; 
the other, Step 2 Clinical Skills 
(CS), is a day-long evaluation of 
clinical skills that takes place at 
one of five standardized-testing 
centers in the United States. Given 
the pass rates among examinees 
and the exam’s cost, we believe 
that Step 2 CS provides a poor 
return on investment and little 
appreciable value to the U.S. 
health care system — and should 
therefore be eliminated.
The NBME and the FSMB 
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